Goldman Sachs analyst Salveen Richter reiterated a Sell rating and $17.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments